We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.


Zenith Strengthens its Management Team with Key Appointments

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Zenith Strengthens its Management Team with Key Appointments"

First Name*
Last Name*
Email Address*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Read time:

Zenith Epigenetics Corp. has announced that it has appointed Joy Zhu, MD, PhD, as Chief Medical Officer, Sanjay Lakhotia, PhD, as Chief Business Officer, and Michael Yakes, PhD, as Vice President Drug Discovery and Exploratory Development.

Dr. Zhu joins Zenith at a pivotal time, just ahead of the first-in-human oncology clinical trials investigating Zenith's proprietary BET inhibitor, ZEN-3365. Dr. Zhu has over 20 years of oncology clinical development experience and has led the design and execution of multiple clinical trials including those resulting in the approval of successful products such as SUTENTÒ and XGEVA.

Prior to joining Zenith, Dr. Zhu held leadership positions at SUGEN/Pfizer, S*BIO Pte Ltd, Amgen, JNJ, and Novartis. Most recently, Dr. Zhu led oncology clinical development at Halozyme Therapeutics.

Dr. Lakhotia brings significant business, operational, and product development expertise to Zenith, with more than two decades of experience at innovative pharmaceutical and biotech companies, including Wyeth Pharmaceuticals, MedImmune, Onyx Pharmaceuticals, Portola Pharmaceuticals, and Pathway Therapeutics. He has contributed to the business development and product development efforts for significant products such as Prevnar, Nexavar, and FluMist.

Dr. Yakes has over 15 years of experience in the discovery and development of novel cancer therapeutics. Prior to joining Zenith, Dr. Yakes held the position of Senior Director, Translational Biology at Cleave Biosciences.

Prior to Cleave Biosciences, he held positions of increasing responsibility at Exelixis, making major contributions to the preclinical characterization and IND/NDA filings for COMETRIQ (cabozantanib).

Dr. Julie Cherrington, President and CEO of Zenith, remarked, "I am very excited to welcome Joy, Sanjay and Mike to Zenith's management team. We have a great foundation to develop a best in class BET inhibitor for the treatment of hematological malignancies and solid tumors in select patient populations. This is a pivotal step in building a leading epigenetics company".